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Epidemic of end-stage renal disease in people with diabetes in
the United States population: Do we know the cause?
Background. The number of individuals initiating renal re-
placement therapy in the United States population grew expo-
nentially over the past two decades. Cases of end-stage renal
diseae (ESRD) attributed to diabetes accounted for most of
this increase. In this report we examined factors that may ac-
count for the increase to determine whether it truly represents
an epidemic of ESRD due to diabetes.
Methods. We reviewed time trends in data of the United
States Renal Data system, the Diabetes Surveillance Program
of the Centers for Disease Control and Prevention, and diabetes
literature.
Results. Recent growth of the number of individuals with di-
abetes accounted for less than 10% of the increase in the num-
ber of diabetes-related ESRD. Instead, most of it was due to a
threefold increase in risk of ESRD in people with diabetes and,
therefore, qualifies as an epidemic. Curiously, this epidemic oc-
curred despite widening implementation of effective renopro-
tective therapies. Individuals with type 2 diabetes, regardless of
gender, age, or race, experienced the greatest increase in risk.
There is no evidence that diabetic patients have been surviving
longer, so the increased risk was not attributable to the high risk
associated with long duration diabetes.
Conclusion. We hypothesize that an epidemic of ESRD has
occurred in people with diabetes in the United States population
over the last two decades. The nature of the factor responsible
for the epidemic and the reasons it affects patients with type 2
diabetes particularly are unknown. Research efforts to identify
the putative factor deserve high priority, as does a commitment
of resources to provide care for the burgeoning number of pa-
tients with ESRD and type 2 diabetes.
The United States Renal Data System (USRDS) is a
roster of individuals accepted for renal replacement ther-
Key words: diabetes mellitus, end-stage renal disease (ESRD), secular
trends, ACE inhibitors, antihypertensive treatments, USRDS.
Received for publication August 7, 2003
and in revised form May 4, 2004
Accepted for publication December 10, 2004
Updated for publication January 7, 2005
C© 2005 by the International Society of Nephrology
apy in the United States [1–3]. It contains information
on nearly 94% of individuals who have initiated renal re-
placement therapy since 1976 [2]. The primary goals of the
USRDS are to provide a description of the populations
initiating or continuing on renal replacement therapy, as
well as assessments of its effectiveness [2, 4]. USRDS
data have been used to evaluate mortality according to
modality of renal replacement therapy or specific com-
ponents of dialysis equipment [5, 6]. In this report we
demonstrate how the USRDS data on individuals with
newly diagnosed ESRD, combined with estimates of the
size of the population with diabetes, can be used to eval-
uate trends in the occurrence of ESRD in the diabetic
population in the United States and to examine possible
determinants of the epidemic of ESRD in this population.
DATA BASES AND METHODS
We obtained the number of individuals initiating treat-
ment for ESRD according to cause for the years 1980
through 1999 from the RenDER system of the USRDS
(http://www.usrds.org). The number of persons with di-
agnosed diabetes in the United States according to age,
gender, race, and calendar year were obtained from
the Diabetes Surveillance Program of the Centers for
Disease Control and Prevention (CDC) (http://www.
cdc.gov/diabetes/statistics/index.htm) and projections of
the numbers up to 2050 were adapted from a recent pub-
lication [7]. Incidence rates (per 100,000 persons with
diabetes) of the initiation of treatment for ESRD re-
lated to diabetes were computed by CDC according to
the same age, gender, and race categories for the years
1984 through 1996 using 3-year rolling averages of the
number of persons initiating ESRD treatment (supplied
by USRDS) and the number of persons with diagnosed
diabetes (Chapter 8, 1999 Diabetes Surveillance Report)
(http://www.cdc.gov/diabetes/statistics/index.htm).
Time trends in age- and race-specific incidence rates
(and gender-specific rates for persons <45 years of age)
between 1984 and 1996 were evaluated by regression
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Fig. 1. The number of individuals initiating treatment for end-stage
renal disease (ESRD) in the United States, according to cause and
calendar year, 1980 to 1999 (RenDER system of the United States Re-
nal Data System (USRDS) (http://www.usrds.org). The vertical line A
marks the publication of the clinical trial showing the renoprotective
effect of angiotensin-converting enzyme (ACE) inhibition [15]. Abbre-
viations are: DM, diabetes mellitus; HTN, hypertension; GN, glomeru-
lonephritis.
methods, giving the incidence rates equal weight. For all
age-, race-, and gender-specific categories of the popula-
tion, a linear term was sufficient to summarize the trend.
Differences between slope parameters were evaluated
in analysis of covariance models (SAS version 8 PROC
GLM; SAS Institute, Inc., Cary, NC, USA) with indicator
variables for group and interaction terms for differences
in slopes.
The SAS PROC FORECAST (SAS Institute, Inc.),
which includes extrapolative forecasting methods for
time series historic data, was used to project the num-
ber of new cases and prevalent cases of ESRD attributed
to diabetes in the United States to 2010. The historic data
were the number of new onset and prevalent cases from
1982 to 2000. We projected each age group independently
by using the stepwise autoregressive method, which com-
bines time trend regression with an autoregressive model.
We also used exponential smoothing and trending to pro-
duce a time trend projection [8].
RESULTS
Increasing number of individuals with new onset ESRD
is primarily due to diabetes
The number of individuals initiating treatment for
newly diagnosed ESRD in the United States population
grew dramatically over the past two decades. During 1982
the number was 22,069. That number doubled (48,353) by
1990 and nearly doubled again (89,318) by 1999. The ex-
ponential nature of this increase was accounted for by
cases of ESRD attributed to diabetes and hypertension
(Fig. 1), while cases attributed to glomerulonephritis or
other causes increased only gradually. In the late 1980s
and in the 1990s, the rate of increase for hypertension-
related cases of ESRD abated somewhat, but the steep
rate of increase for diabetes-related cases of ESRD has
continued unabated.
Can this increase be due to changes in the assignment
of causes of ESRD?
Admittedly, recent attention to diabetes may have in-
creased the inclination of doctors to list diabetes as the
primary cause of ESRD when another cause, such as hy-
pertension, was also present. However, already in the
1980s, almost all ESRD patients with both hypertension
and diabetes were classified as having ESRD due to dia-
betes [9], so a large increase due to reclassification was not
possible. Additional data regarding a possible trend in the
assignment of primary cause of ESRD are available for
the 6-year period from 1996 to 2001 (unpublished data,
USRDS). During that time, the number of newly regis-
tered cases of ESRD with both diabetes and hypertension
listed on the Medical Evidence Form (either as primary
cause or as comorbid condition) grew 33%, from 34,852
to 46,208. In 1996, when there were 34,852 cases, 91%
were attributed to diabetes and in 2001, when there were
46,208 cases, doctors attributed 89% to diabetes. Thus, in
patients with both conditions, no shift from a diagnosis
of hypertensive ESRD to diabetic ESRD has occurred in
recent years.
Does the increasing number of individuals with ESRD
due to diabetes result from the rising prevalence
of diabetes?
According to the Diabetes Surveillance Program of the
CDC, between 1984 and 1996 the population of individu-
als with diabetes in the United States grew 40% (from 6.1
to 8.5 million), while the increment in the number of per-
sons initiating treatment for ESRD attributed to diabetes
was more than 300% (from 6981 to 31,647). If the age-
specific incidence rates of ESRD in that population had
remained unchanged, the number of persons initiating
treatment for ESRD attributed to diabetes would have
grown only to 9548 in 1996, an increment of 2576. The ac-
tual increment of 24,666 cases (tenfold that attributable
to growth of the population at risk) can only mean that
the risk of developing ESRD (being accepted to a renal
replacement therapy program) increased in patients with
diabetes between 1984 and 1996. This is clearly illustrated
if the data are presented as the incidence rate of ESRD
in the population with diabetes in the United States.
The rising risk of ESRD in patients with diabetes
The incidence rate of ESRD in the population with
diabetes is shown in Figure 2 for calendar years 1984 to
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Fig. 2. Incidence rates of treated end-stage renal disease (ESRD) attributed to diabetes per 100,000 individuals with diagnosed diabetes in the
United States, 1984 to 1996. The vertical line A marks the publication of the clinical trial showing the renoprotective effect of angiotensin-converting
enzyme (ACE) inhibition [15]. Rates are shown separately for non-Hispanic whites (left panel) and non-Hispanic blacks (right panel). For ages
<45 years (upper graphs) males and females are shown separately, while for older age groups (lower graphs) the genders were combined since
their rates were similar. Data are based on National Health Interview Survey estimates of the number of persons with diabetes and United States
Renal Data System (USRDS) data on the number of persons with incident ESRD attributed to diabetes (1999 Diabetes Surveillance Report,
http://www.cdc.gov/diabetes/statistics/index.htm).
1996 according to age and race. Among whites (Fig. 2, left
panel), most of the diabetes in the youngest age group
(younger than 45 years) can be considered as type 1 and
in the older age groups as type 2. Gender-specific rates
are shown for the youngest age group because the inci-
dence rate in women was about half that seen in men, but
the combined rate is shown for older age groups where
the gender-specific rates were similar. In all groups,
the incidence rate of ESRD increased over the 13-year
time frame. Initially the incidence rates of the three oldest
age groups were lower than that in the youngest group,
but they increased more steeply and exceeded or matched
the rate in the young by 1996. Among blacks, where type
2 diabetes predominates in all age groups, age-specific
incidence rates of ESRD (Fig. 2, right panel) were twice
those for whites and increased similarly over the 13-year
time frame. By 1996, the age-adjusted rates were 590.3
versus 312.1 per 100,000 diabetics per year, for blacks
and whites, respectively. Except for the absence of a gen-
der difference in the youngest age group, the age-specific
trends paralleled those in whites.
To summarize the secular trends in incidence rates of
ESRD in the population with diabetes, the age-specific
incidence rates were regressed against calendar year, the
slope representing the average annual increment in risk
of ESRD (Table 1). Among whites younger than age
45 years, the slopes fit to the gender-specific incidence
rates were significant for both women and men (P = 0.049
and P = 0.01, respectively), and the slope for women was
significantly less than for men, 2.8 versus 7.3 cases per
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Table 1. Average annual increment in the incidence rate of end-stage
renal disease (ESRD) attributed to diabetes in people with diabetes in
the United States population during the period 1984 to 1996,
according to age and race
Individuals with diabetes
Age groups years White Black
Average annual increments in risk of ESRD per 100,000
<45 women 2.8 20.9
<45 men 7.3 15.9
45–64 19.2 34.3
65–74 25.6a 50.1b
74+ 15.4 36.1
aP < 0.0001 in comparison with other age groups; bP < 0.006 in comparison
with other age groups.
100,000 per year, respectively (P = 0.03). Although sig-
nificant, these slopes pale in comparison with the steeper
slopes in the older age groups (19, 26, and 15 cases
per 100,000 per year for the age groups 45 to 64, 65 to
74, and 75+ years, respectively; P < 0.0001). Curiously,
the annual increments in the incidence rate of ESRD
were significantly higher in the age group 65 to 74 years
(P < 0.0001) than in the age groups 45 to 64 or 75+ years.
Among blacks, the trends in age-specific rates were simi-
lar and proportionate to those for whites (i.e., about twice
as large) (Table 1).
Has the incidence of ESRD been artificially inflated
by increased access to renal replacement therapy or
increased acceptance of it by individuals with diabetes?
Renal replacement therapy has been widely available
in the United States since the middle 1980s [1], and the
cost has been largely covered by the Medicare ESRD
program for the last 30 years [2]. However, within certain
segments of the population such as the elderly, delays
in access or acceptance of renal replacement therapy re-
sulted in an undercounting of the ESRD population [10].
Removal of these barriers and more complete ascertain-
ment of the ESRD population would result in an apparent
increase in the incidence rate over time. The white popu-
lation in the age group 45 to 64 years is a segment of the
population that would have encountered the fewest rea-
sons for delayed access or acceptance, and the incidence
rate of ESRD in this group has increased steadily since
1984 (Fig. 2, left panel). In contrast, the incidence rate of
ESRD in blacks in the age group 75+ years was constant
until around 1988 when it began increasing steeply (Fig. 2,
right panel). After a few years, the steep increase abated
and the continuing increase paralleled the younger age
groups. This pattern is consistent with delayed access or
acceptance of renal replacement therapy in this segment
of the population. Thus, undoubtedly, increasing access
or acceptance has contributed to the overall increase in
the incidence rate of ESRD in the diabetic population,
but these factors are unlikely to have contributed mate-
rially to the threefold increase in the incidence rate from
107.0 to 337.7 per 100,000 in the age group 45 to 64 years
in the white population.
Risk of ESRD in people with diabetes is increasing
despite widening availability of effective interventions
In the early 1980s, Danish authors reported that treat-
ment of hypertension in patients with type 1 diabetes
and proteinuria slowed down the loss of renal function
[11, 12]. Subsequently the beneficial effect of treatment
of hypertension was confirmed in larger studies in pa-
tients with type 1 and type 2 diabetes [13, 14], and the use
of angiotensin-converting enzyme (ACE) inhibitors was
shown specifically to have renoprotective effects [15–20].
Similar effectiveness was demonstrated recently for treat-
ment with angiotensin receptor antagonists [21–23]. All
of these demonstrations of effectiveness, however, have
been based on short-term follow-up, and the long-term
effects of these interventions remain unknown.
Implementation of these interventions in the United
States population has a short history. Antihypertensive
treatment of patients with diabetes was suggested in
the early 1970s [24] but infrequently implemented. Ac-
cording to the 1976 to 1980 NHANES II survey of the
population aged 18 years and older, 44% of the individu-
als with hypertension were treated with antihypertensive
agents [25]. Since then, the prevalence of treated hyper-
tension has increased progressively in the diabetic pop-
ulation so that by the time of the NHANES III survey
(1988 to 1994), the proportion treated with antihyperten-
sive agents had nearly doubled to 82% [26].
The major classes of antihypertensive drugs in use in
the United States population have also changed over
the past two decades [27, 28]. In 1982, antihypertensive
treatment was recommended only if blood pressure was
greater than or equal to 160/95 mm Hg; and the prin-
cipal drugs were thiazide diuretics, beta blockers, cen-
tral adrenergic agonists, and peripheral vasodilators such
as hydralazine. Between 1982 and 1993, blood pressure
treatment goals were lowered to 140/90 mm Hg, and use
of ACE inhibitors became widespread. After ACE in-
hibitors were recommended specifically for the preven-
tion of declining renal function in type 1 diabetes in 1993
[15], treatment with ACE inhibitors was instituted in a
large proportion (45%) of patients with diabetes [29],
and the proportions became even higher if hypertension
or microalbuminuria was present (62% to 80%) [30].
Despite the success in implementing antihypertensive
treatment in individuals with type 1 or type 2 diabetes and
widespread use of ACE inhibition, no tempering of the
rising risk of diabetes-related ESRD has yet appeared in
any age category in the United States population (Figs. 1
and 2). In striking contrast, the annual increase in the
1688 Jones et al: Epidemic of end-stage renal disease in people with diabetes
number of incident cases of ESRD attributed to hyper-
tension has slackened since 1989 (Fig. 1). The reason for
the absence of a similar slackening in the annual increase
in ESRD attributed to diabetes is unknown.
Has improved treatment of diabetes and hypertension
allowed more patients to survive long enough to
develop ESRD?
ESRD is a late-appearing complication of diabetes, the
risk rising significantly after 10 to 15 years duration of dia-
betes [31]. If survival of the population with diabetes has
been prolonged by better treatment, particularly treat-
ment of cardiovascular disease, the major cause of death
in this population, patients with diabetes of such long du-
ration would comprise a growing fraction of the diabetic
population. The result would be both a growing preva-
lence of diabetes and a rising incidence rate of ESRD
related to diabetes, not because of changing risk but be-
cause of the growing proportion of them at high risk due
to long duration diabetes.
Very strong evidence against this hypothesis comes
from several sources. First, consider the supposed post-
ponement of cardiovascular mortality in patients with di-
abetes. The recently reported clinical trial (RENAAL) of
the effectiveness of angiotensin II receptor blockade in
patients with type 2 diabetes and nephropathy examined
both the incidence of ESRD and the mortality rate from
cardiovascular disease [21]. By the end of that 4-year trial,
the cumulative incidence of ESRD in the treated group
was 25%, while it had reached 25% in the placebo group
roughly a year earlier. Thus treatment with angiotensin
II receptor blockade slowed down the rate of the devel-
opment of ESRD by 1 year. Surprisingly, this treatment
had no effect on the morality rate. Both the morbidity
and mortality from cardiovascular causes were similar in
the treated and placebo groups. Management of these
patients under the carefully controlled conditions of a
clinical trial did not extend their duration of diabetes
and reduced, rather than increased, the number of ESRD
events within the 4-year span of the trial. Therefore, none
of the increase in ESRD can be attributed to reduced car-
diovascular mortality due to better disease management
with interruption of the renin-angiotensin system.
Population data on cardiovascular mortality in patients
with diabetes are consistent with the RENAAL results in
finding no evidence for a substantial reduction in cardio-
vascular disease mortality in people with diabetes during
the last 20 years. The National Center for Health Statistics
followed two representative samples of the United States
population (NHANES I in 1971 to 1975 and NHANES
I Epidemiologic Follow-up Survey in 1982 to 1984) for 8
to 9 years. The individuals with diabetes in these samples
were mainly patients with type 2 diabetes. Age-adjusted
heart disease mortality rate fell only 13% in diabetic
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Fig. 3. Age-adjusted prevalence of diabetes (diagnosed and undiag-
nosed) in adults aged 20 years and older in the United States population
according to race and time period [34]. DM is diabetes mellitus.
men and actually rose 23% in diabetic women, at the
same time it was falling by 36% and 27% in nondiabetic
men and women, respectively [32]. In the same study, all-
cause mortality declined only minimally in people with
diabetes. In the absence of a decrease in mortality, it is
difficult to justify a claim that better treatment has ex-
tended survival and increased the duration of diabetes in
the population.
Moreover, the population based study of patients with
type 2 diabetes in Rochester, Minnesota, does not support
the hypothesis that a secular trend in the proportion of
patients with long duration diabetes can account for the
increasing risk of ESRD [33]. Data from three decades
(1970s, 1980s, and 1990s) were analyzed, and there was
no change in the mean duration of type 2 diabetes and no
secular increase in the incidence of proteinuria after the
diagnosis of diabetes to account for the secular increase
in ESRD.
Further evidence, albeit indirect, against any increase
in the duration of diabetes in the United States popula-
tion, comes from a recent report from CDC that assessed
change in the prevalence of diabetes (diagnosed and un-
diagnosed) in the United States population during the last
decade by comparing data from NHANES IV (conducted
in 1999 and 2000) with data from NHANES III (con-
ducted in 1988 to 1994). Surprisingly, the prevalence of
diabetes in the population age 20 years and older changed
little over time [34]. In the white population, the age-
adjusted prevalence of diabetes was 7.4% in both surveys,
while it increased from 12.3% to 14.9% in blacks (Fig. 3).
Any increase in the average duration of diabetes in the
population would increase the population size. Therefore,
a stable prevalence of diabetes in the adult white popula-
tion does not support a hypothesis that the proportion of
patients with long duration diabetes is increasing in the
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United States population. Furthermore, the rising preva-
lence of diagnosed diabetes and decreasing prevalence
of undiagnosed diabetes in the black population implies
that a large number of newly diagnosed patients were
added to the population, reducing the proportion of the
black population with long duration diabetes.
DISCUSSION
The epidemic of ESRD in the population with diabetes
is real
The aggregate data sources used in this review pro-
vide an opportunity to examine time trends in a situation
where individual data are not available. Unfortunately,
this type of study design is subject to a number of limita-
tions that readers must take into account when interpret-
ing the findings. One factor that may have contributed
substantially to the growth of the ESRD population was
improved ascertainment by USRDS of ESRD over time.
Moreover, since only patients who accept treatment are
registered with USRDS, increasing acceptance of renal
replacement therapy among diabetic patients may also
have accelerated growth of the number of cases. Evidence
to support a concern that problems of ascertainment or
acceptance did affect the trends is seen in the eldest age
group in the black population (Fig. 2). There was a lag of
almost a decade before the incidence rate in that group
began to increase in parallel with other age groups. How-
ever, evidence that these factors cannot account for more
than a fraction of the increased number of registered new
cases of ESRD each year is seen in the steady increase
in the incidence rate of ESRD attributed to diabetes in
the age group 45 to 64 years in the white population
(Fig. 2). In this working-age segment of the population,
which would be motivated to seek renal replacement ther-
apy and would encounter few of the barriers that might
deter individuals of similar age in a minority population,
the incidence rate of 107.0 per 100,000 individuals with
diabetes in 1984 had doubled to 216.6 per 100,000 in 1990
and tripled to 337.7 per 100,000 by 1996. It is not plausible
that ascertainment and acceptance of renal replacement
therapy tripled in this population segment since 1984.
Other potential pitfalls of this study design that might
explain some of the rising incidence of ESRD in the pop-
ulation with diabetes include changing preferences for
the assignment of primary cause of ESRD and increasing
prevalence of long duration diabetes in the population.
The possible impacts of these pitfalls on the findings were
addressed specifically, and no evidence that they con-
tributed substantially to the rising incidence was found.
The threefold increase in risk of ESRD in the popula-
tion with diabetes cannot be attributed to improved pre-
vention of cardiovascular mortality or to an increase in
the proportion of patients surviving diabetes long enough
to experience serious kidney complications. While inves-
tigators with the Framingham Heart Study have reported
a reduction in the incidence rate of cardiovascular events
between the time periods 1950 to 1966 and 1977 to 1995,
they did not examine whether there was a change in inci-
dence within the latter time period [35]. However, an ear-
lier report specifically on the increase in cases of ESRD
attributed to diabetes during that later time period (be-
tween 1978 and 1991) examined the contribution of im-
proved cardiovascular mortality on the increase and came
to a conclusion similar to ours [36]. Using an approach
different from ours, they concluded that increased preva-
lence of diabetes and improved myocardial infarction
and stroke survival during that interval were insufficient
to account for the increase in diabetes-related ESRD.
They did not infer explicitly, however, that in order to
account for the rest of the increase, the risk of ESRD in
the population with diabetes must have increased. There-
fore, we must postulate the existence of some unknown
factor (deleterious exposure) that hastens the loss of re-
nal function in this population. Furthermore, exposure to
that factor must have increased in prevalence or intensity
over the last several decades.
Similar increases in the incidence of patients with
ESRD and type 2 diabetes have been reported in many
countries around the world, as reviewed by Ritz et al
[37]. Unlike the trend in the United States, it is difficult
to determine the extent to which these trends are due to
increasing risk of ESRD as opposed to increasing access
and acceptance of renal replacement therapy.
Implications for future research on etiology and
prevention of ESRD in diabetes
Several areas of research require urgent attention. One
high priority area for research is the natural history of
renal function loss in individuals with diabetes. Hereto-
fore, research has focused on the continuing loss that
occurs after impaired renal function has become estab-
lished, which we can consider “advanced renal function
loss.” Earlier in the process, opportunities for effective
intervention may become evident through knowledge of
the natural history of “early renal function loss.” Fur-
thermore, the concept that proteinuria plays an essen-
tial role in the process must be re-examined. The risk of
ESRD has increased without any clear evidence for an
increasing risk of proteinuria in the population with dia-
betes. Therefore, either the probability of progressing to
ESRD in patients with diabetes and proteinuria has in-
creased or declining renal function occurs in patients with
diabetes before proteinuria develops. Thus, prospective
studies are needed to examine renal function decline in
individuals with diabetes and normoalbuminuria or mi-
croalbuminuria.
The second area of research is an epidemiologic
inquiry into risk factors and risk indicators for the
1690 Jones et al: Epidemic of end-stage renal disease in people with diabetes
development of ESRD in diabetes that have increased
over time and could account for the observed epidemic.
Given the goal of identifying determinants of early renal
function decline, particular attention should be paid to
characteristics of patients with diabetes before nephropa-
thy has developed (such as the use of prescription or
nonprescription medications) and should include the an-
tecedents of diabetes itself (such as obesity in the case of
type 2 diabetes).
A secular increase in obesity, the most important risk
factor for type 2 diabetes, has been amply documented.
Both absolute body weight and the prevalence of obesity
have increased in the United States population in recent
decades [38, 39]. Furthermore, the population with dia-
betes has shared in the general trend of increasing obesity.
In 1970 to 1974, 33% of the patients with newly diagnosed
type 2 diabetes in Rochester, Minnesota, were obese as
compared to 49% in 1985 to 1989 [40]. The evidence link-
ing obesity as a risk factor for ESRD is tenuous, and more
research needs to be done. Similarly, other antecedents
of glucose intolerance need to be examined for their pos-
sible effects on renal function loss at the same time that
they are predisposing to diabetes.
Regarding secular changes in the treatment of persons
with diabetes, one example has already been discussed,
the increasing proportion treated with antihypertensive
agents and ACE inhibitors. An argument against consid-
ering them as contributors to the rising risk of ESRD is
the fact that patients with hypertension have also experi-
enced a similar secular increase in treatment with these
agents but the occurrence of ESRD attributed to hyper-
tension leveled off in the 1990s and did not increase in
parallel with diabetes-related ESRD (Fig. 1).
Other prescription medicines ought to be considered
as well. Individuals with diabetes are 1.7 to 2.1 times
more likely to receive prescription medicines than non-
diabetics, even after excluding antidiabetic medications
[41]. The pharmacologic properties of some commonly
used medications are modified in the presence of diabetes
[42], but the consequences for the kidneys have not been
studied. An exception is the potential nephrotoxicity of
over-the-counter analgesics such as acetaminophen and
nonsteroidal anti-inflammatory medicines, which have
been examined in case control studies. While the Physi-
cian’s Health Study of a cohort of nondiabetic men did not
detect any association between analgesic use and moder-
ate renal insufficiency [43], a population-based study in
Sweden found an increased risk of chronic renal insuffi-
ciency associated with use of acetaminophen or aspirin in
people with diabetes [44].
Implications for patient care
The increasing risk of ESRD in diabetes, if unabated,
will increase enormously the number of new cases of
Table 2. Number of new onset and prevalent cases with
diabetes-related end-stage renal disease (ESRD) in the United States
population observed in 2000 and predicted for 2010
Number of individuals with
diabetes-related ESRD
Age groups years Observed in 2000 Estimated in 2010
New onset cases
<45 years 4106 4448
45–64 17,834 26,420
65–74 12,167 19,096
75 + 7665 19,172
Total 41,772 69,136
Prevalent cases
<45 years 17,742 18,329
45–64 60,224 96,945
65–74 34,872 64,531
75+ 18,335 54,079
Total 131,173 233,884
ESRD in the United States population during the next
10 years (Table 2). The number of individuals with newly
diagnosed ESRD due to diabetes in the year 2000 was
41,772 and by the year 2010 this number is predicted to
reach 69,136 individuals, an increase of 65.5%. The total
number of individuals on renal replacement therapy with
ESRD due to diabetes in 2000, new cases plus the carry-
over from previous years, was 131,173, and the number is
predicted to be 233,884 in 2010, a 78.3% increase.
The increase in prevalence of patients with diabetes-
related ESRD in the United States will place a dispropor-
tionate burden on the ESRD health care delivery system.
In addition to the resources usually required for renal re-
placement therapy, ESRD patients with diabetes require
specialized resources to maintain their glycemic control
and treat diabetes-related complications, such as diabetic
retinopathy, peripheral vascular disease, and coronary
artery disease. Moreover, the age group 75+ years will
experience the largest relative increases The more com-
prehensive care needed by these patients will require ad-
ditional staff: diabetes specialists and nurses as well as
nephrologists and technicians, providers who are already
in short supply. Furthermore, the unique needs of the
diabetic population must be incorporated into the train-
ing programs for all the staff. Planning for the projected
growth in requirements for resources, which will occur in
the near future, requires urgent attention.
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